Table 2 Comparison of remission and non-remission groups at 52 weeks

Age (years)

32.1 ± 10.5

34.9 ± 10.1

0.3201^a

Gender (male)

75.6 % (31/41)

71.4 % (15/21)

0.7648^c

Disease duration (months)

87.0 (0.0–480.0)

144.0 (0.0–336.0)

0.3964^b

Disease duration < 2 years

36.6 % (15/41)

23.8 % (5/21)

0.3962^c

Colonic type

4.9 % (2/41)

23.8 (5/21)

*0.0387^c

Surgery

61.0 % (25/41)

66.7 % (14/21)

0.7837^c

Extra fistula

30.0 % (12/40)

42.9 % (9/21)

0.3980^c

Intra fistula

7.5 % (3/40)

9.5 % (2/21)

>0.9999^c

Perianal disease

46.3 % (19/41)

52.4 % (11/21)

0.7895^c

Smoking

17.6 % (6/34)

16.7 % (3/18)

>0.9999^c

Concomitant use

 5-Aminosalicylates

87.8 % (36/41)

100 % (21/21)

0.1569^c

 Steroids

9.8 % (4/41)

9.5 % (2/21)

>0.9999^c

 Immunomodulators

22.0 % (9/41)

28.6 % (6/21)

0.7548^c

 Elemental diet

65.9 % (27/41)

57.1 % (12/21)

0.5829^c

IFX experience

 Experience with IFX

51.2 % (21/41)

57.1 % (12/21)

0.7895^c

 Double dose

28.6 % (6/21)

41.7 % (5/12)

0.4713^c

 Duration of IFX use (months)

19.5 (1.0–84.0)

10.0 (1.0–100)

0.7818^b

 Reason of switch

0.5700^d

  PNR

10.0 % (2/20)

0.0 % (0/12)

  SNR

45.0 % (9/20)

50.0 % (6/12)

  Intolerance

40.0 % (8/20)

50.0 % (6/12)

  Other

5.0 % (1/20)

0.0 % (0/12)

CDAI at baseline (points)

169.5 ± 76.8

215.4 ± 67.2

*0.0236^a

CRP at baseline (mg/dL)

0.70 (0.00–6.86)

0.88 (0.02–6.34)

0.4436^b